BioNexus Gene Lab Corp.

Equities

BGLC

US0906282076

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.5935 USD +0.15% Intraday chart for BioNexus Gene Lab Corp. -1.05% +11.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioNexus Gene Lab Corp. Provides Information to Shareholders CI
Certain Common Stock of BioNexus Gene Lab Corp. are subject to a Lock-Up Agreement Ending on 18-JAN-2024. CI
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp CI
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bionexus Gene Lab Corp. Announces Resignation of Wei Li Leong as Chief Financial Officer CI
BioNexus Gene Lab Names Chi Yuen Leong as CEO MT
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer CI
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director CI
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer CI
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Board of Directors CI
BioNexus Gene Lab Corp. Announces Executive Changes CI
Top Premarket Gainers MT
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioNexus Gene Lab Raises $5.8 Million from Public Share Offering MT
BioNexus Gene Lab Corp.(NasdaqCM:BGLC) added to NASDAQ Composite Index CI
Top Midday Gainers MT
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note MT
Investors Look to Close Week on Positive Note as US Futures See Mixed Performance Premarket Friday MT
Top Premarket Gainers MT
BioNexus Gene Lab Corp. has completed an IPO in the amount of $5 million. CI
BioNexus Gene Lab Shares Fall in Nasdaq Debut MT
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BioNexus Gene Lab Corp. has filed an IPO in the amount of $17.25 million. CI
Chart BioNexus Gene Lab Corp.
More charts
BioNexus Gene Lab Corp., through its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., focuses on the wholesale of chemical raw material products. The Company is engaged in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. The Company is also engaged in the business of developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. It offers a range of fiberglass reinforced plastic (FRP) products, which include Polyester Resin SHCP 268, Polyester Resin 9509 and Polyester Resin 2802. The FRP and other raw materials it offers are used to produce a variety of goods, including handrails, bench tops, cleanroom panels, and covers for various instruments used in manufacturing.
More about the company
  1. Stock Market
  2. Equities
  3. BGLC Stock
  4. News BioNexus Gene Lab Corp.
  5. BioNexus Gene Lab Names Chi Yuen Leong as CEO